Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | IDUA | P35475 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18911637 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL12346259 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL13618641 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL24212766 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL4267050 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL23720424 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL13792996 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL15061094 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL21097517 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL17828572 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709714-A1 | SUBSTITUTED QUINOXALINES | Mirati Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260027103-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A QUINOLONE COMPOUND FOR IRRITABLE BOWEL SYNDROME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-01-29 | — | — | US | claimed |
| US-20250325676-A1 | CAMPTOTHECIN PRODRUG AND PHARMACEUTICAL COMPOSITION THEREOF | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2025-10-23 | — | — | US | claimed |
| EP-4554588-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A QUINOLONE COMPOUND FOR IRRITABLE BOWEL SYNDROME | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-05-21 | — | — | EP | claimed |
| CN-119451970-A | N-substituted indole derivatives and conjugates thereof for the treatment of cancer | 埃维克斯塔生物公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119343138-A | Pharmaceutical composition for irritable bowel syndrome comprising quinolone compounds | 大塚制药株式会社 | 2025-01-21 | — | — | CN | claimed |
| CN-119212997-A | Indazoles as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) and methods of use thereof | 第一生物治疗股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| WO-2024238221-A1 | SUBSTITUTED QUINOXALINES | Mirati Therapeutics, Inc. (US) | 2024-11-21 | — | — | WO | claimed |
| WO-2024012421-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A QUINOLONE COMPOUND FOR IRRITABLE BOWEL SYNDROME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | WO | claimed |
| CN-117263999-A | Camptothecin prodrugs and pharmaceutical compositions thereof | 天津和美奥康医药科技有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-111278821-B | Spiro compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-10-03 | — | — | CN | claimed |
| CN-111278817-B | Polycyclic compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-05-16 | — | — | CN | claimed |
| WO-2023277656-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | (주)스파크바이오파마 | 2023-01-05 | — | — | WO | claimed |
| CN-115038445-A | Novel medicaments for the treatment of inflammatory diseases | 大塚制药株式会社 | 2022-09-09 | — | — | CN | claimed |
| CN-114929224-A | Novel medicine for treating hepatic encephalopathy | 大塚制药株式会社 | 2022-08-19 | — | — | CN | claimed |
| WO-2022048529-A1 | FORSYTHIAE FRUCTUS COMPONENT AND OPTIONAL GINSENG COMPONENT, AND USE THEREOF | 大连富生天然药物开发有限公司 | 2022-03-10 | — | — | WO | claimed |
| WO-2018165250-A1 | GLUCURONIDE PRODRUGS OF TOFACITINIB | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-09-13 | — | — | WO | claimed |
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | PFIZER INC. | 2007-01-04 | — | — | US | claimed |
| EP-1670765-A2 | CETP INHIBITORS AND METABOLITES THEREOF | Pfizer Products Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2005033082-A2 | CETP INHIBITORS AND METABOLITES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-04-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | CETP, LCAT, MTTP | SUCNR1 2230/4885THRB 280/4885LMNA 1724/4885 |
| US-20260027103-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A QUINOLONE COMPOUND FOR IRRITABLE BOWEL SYNDROME | SI, VIP, SLC10A2 | SUCNR1 21/4885THRB 3831/4885LMNA 3350/4885 |
| US-20250325676-A1 | CAMPTOTHECIN PRODRUG AND PHARMACEUTICAL COMPOSITION THEREOF | TOP2B, PDE10A, REV1 | SUCNR1 1132/4885THRB 946/4885LMNA 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.